Lilly Q1 Earnings Call (April 30): Retatrutide TRANSCEND T2D1 First Phase 3 in Type 2 Diabetes — A1c Down 1.7–2.0 Pts, 25–37 lb Mean Weight Loss
On the April 30 Q1 2026 call, Eli Lilly disclosed positive topline results from TRANSCEND T2D1, the first Phase 3 trial of retatrutide (triple GLP-1/GIP/glucagon agonist) in adults with type 2 diabetes. Compared with placebo, retatrutide lowered A1c by an average of 1.7 to 2.0 percentage points across doses and produced mean weight loss of 11.1 to 16.6 kilograms (25 to 37 pounds). The data complement the previously reported TRIUMPH-4 obesity-with-knee-osteoarthritis results (28.7% weight loss, 75.8% pain reduction). TRIUMPH-1, an 80-week obesity study, is the next retatrutide readout expected, with seven additional Phase 3 readouts still to come in 2026 ahead of a planned regulatory submission late 2026 or 2027.